Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas - A therapeutic target?

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 11-19

  García, Mario Pérez Sayáns ^a,c   Suárez Peñaranda, José Manuel ^b   Gayoso Diz, Pilar ^b   Barros Angueira, Francisco ^b   Gándara Rey, José Manuel ^c   García García, Abel ^a,c  

^a Santiago University Clinical Hospital   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c Hospital Clinico Universitario ^*  (Spain)

Author keywords

Matrix metalloproteinases (MMPs); Metalloproteinases inhibitors (MMIs); Oral squamous cell carcinomas (OSCC); Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AE 941; ALENDRONIC ACID; BATIMASTAT; CELECOXIB; CGS 27023A; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DOXYCYCLINE HYCLATE; ENDOSTATIN; FLAVONOID; GEFITINIB; ILOMASTAT; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MINODRONIC ACID; PAMIDRONIC ACID; PRINOMASTAT; REBIMASTAT; RETINOIC ACID; RETINOID; SILIBININ; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNINDEXED DRUG; ZOLEDRONIC ACID;

CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME MECHANISM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TISSUE INHIBITOR OF METALLOPROTEINASE 2 GENE; TUMOR SUPPRESSOR GENE;

EID: 84861808967     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.040     Document Type: Review

References (93)

1. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature. 2004, 432:332-337.
2. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993, 9:541-573.
3. Friedl P., Wolf K. Tube travel: The role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008, 68:7247-7249.
4. Hojilla C.V., Wood G.A., Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008, 10:205.
5. Decock J., Thirkettle S., Wagstaff L., Edwards D.R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 2011, 15:1254-1265.
6. Rucci N., Sanita P., Angelucci A. Expanding view of the role of matrix metalloproteases in metastatic growth. Curr. Mol. Med. 2011.
7. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer. 2002, 2:657-672.
8. Burton-Wurster N., Lust G., Macleod J.N. Cartilage fibronectin isoforms: in search of functions for a special population of matrix glycoproteins. Matrix Biol. 1997, 15:441-454.
9. Yang Z., Strickland D.K., Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 2001, 276:8403-8408.
10. Douglas D.A., Shi Y.E., Sang Q.A. Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J. Protein Chem. 1997, 16:237-255.
11. Bigg H.F., Shi Y.E., Liu Y.E., Steffensen B., Overall C.M. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem. 1997, 272:15496-15500.
12. Yang S.F., Yang W.E., Kuo W.H., Chang H.R., Chu S.C., Hsieh Y.S. Antimetastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases. Arch. Oral Biol. 2008, 53:287-294.
13. Hernandez-Barrantes S., Toth M., Bernardo M.M., Yurkova M., Gervasi D.C., Raz Y., Sang Q.A., Fridman R. Binding of active (57kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 2000, 275:12080-12089.
14. Caterina J.J., Yamada S., Caterina N.C., Longenecker G., Holmback K., Shi J., Yermovsky A.E., Engler J.A., Birkedal-Hansen H. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(timp-2) gene alters proMMP-2 activation. J. Biol. Chem. 2000, 275:26416-26422.
15. English J.L., Kassiri Z., Koskivirta I., Atkinson S.J., Di Grappa M., Soloway P.D., Nagase H., Vuorio E., Murphy G., Khokha R. Individual timp deficiencies differentially impact pro-MMP-2 activation. J. Biol. Chem. 2006, 281:10337-10346.
16. Thomas G.T., Lewis M.P., Speight P.M. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999, 35:227-233.
17. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. 1994, 86:299-304.
18. Imren S., Kohn D.B., Shimada H., Blavier L., DeClerck Y.A. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 1996, 56:2891-2895.
19. Poulsom R., Pignatelli M., Stetler-Stevenson W.G., Liotta L.A., Wright P.A., Jeffery R.E., Longcroft J.M., Rogers L., Stamp G.W. Stromal expression of 72kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 1992, 141:389-396.
20. Okada Y. Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. Verh. Dtsch. Ges. Pathol. 2000, 84:33-42.
21. Shiomi T., Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003, 22:145-152.
22. de Vicente J.C., Fresno M.F., Villalain L., Vega J.A., Lopez Arranz J.S. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma. Oral Oncol. 2005, 41:568-579.
23. Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T., Nonaka S., Harabuchi Y. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin. Cancer Res. 2004, 10:634-640.
24. Shimada T., Nakamura H., Yamashita K., Kawata R., Murakami Y., Fujimoto N., Sato H., Seiki M., Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin. Exp. Metastasis 2000, 18:179-188.
25. de Vicente J.C., Lequerica-Fernandez P., Santamaria J., Fresno M.F. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J. Oral Pathol. Med. 2007, 36:415-424.
26. Singh R.D., Haridas N., Patel J.B., Shah F.D., Shukla S.N., Shah P.M., Patel P.S. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian. J. Clin. Biochem. 2010, 25:250-259.
27. Baker E.A., Leaper D.J., Hayter J.P., Dickenson A.J. The matrix metalloproteinase system in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 2006, 44:482-486.
28. Schmalbach C.E., Chepeha D.B., Giordano T.J., et al. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 2004, 130:295-302.
29. Kurahara S., Shinohara M., Ikebe T., Nakamura S., Beppu M., Hiraki A., Takeuchi H., Shirasuna K. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999, 21:627-638.
30. Ikebe T., Shinohara M., Takeuchi H., Beppu M., Kurahara S., Nakamura S., Shirasuna K. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin. Exp. Metastasis 1999, 17:315-323.
31. Gao Z.B., Duan Y.Q., Zhang L., Chen D.W., Ding P.T. Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Int. J. Mol. Med. 2005, 16:599-603.
32. Gray S.T., Wilkins R.J., Yun K. Interstitial collagenase gene expression in oral squamous cell carcinoma. Am. J. Pathol. 1992, 141:301-306.
33. Birkedal-Hansen B., Pavelic Z.P., Gluckman J.L., Stambrook P., Li Y.Q., Stetler-Stevenson W.G. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis. 2000, 6:376-382.
34. Sutinen M., Kainulainen T., Hurskainen T., Vesterlund E., Alexander J.P., Overall C.M., Sorsa T., Salo T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br. J. Cancer 1998, 77:2239-2245.
35. Vairaktaris E., Yapijakis C., Yiannopoulos A., et al. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol. Rep. 2007, 17:963-968.
36. Vairaktaris E., Serefoglou Z., Avgoustidis D., et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol. 2009, 45:247-253.
37. Pradhan-Palikhe P., Vesterinen T., Tarkkanen J., Leivo I., Sorsa T., Salo T., Mattila P.S. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncol. 2010, 46:514-518.
38. Duong H.S., Le A.D., Zhang Q., Messadi D.V. A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion. Int. J. Exp. Pathol. 2005, 86:365-374.
39. Juarez J., Clayman G., Nakajima M., Tanabe K.K., Saya H., Nicolson G.L., Boyd D. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int. J. Cancer 1993, 55:10-18.
40. Kinsenn H., Sato H., Furukawa M., Yoshizaki T. Modulation of cell growth and matrix metalloproteinase-2 activation of oral squamous cell carcinoma as a function of culture condition with type I collagen. Acta Otolaryngol. 2003, 123:987-993.
41. Nii M., Kayada Y., Yoshiga K., Takada K., Okamoto T., Yanagihara K. Suppression of metastasis by tissue inhibitor of metalloproteinase-1 in a newly established human oral squamous cell carcinoma cell line. Int. J. Oncol. 2000, 16:119-124.
42. Nii M., Kayada Y., Yoshiga K., Takada K., Yanagihara K. Expression of type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in newly established human oral malignant tumor lines. Jpn. J. Clin. Oncol. 1996, 26:117-123.
43. Kawamata H., Nakashiro K., Uchida D., Harada K., Yoshida H., Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int. J. Cancer 1997, 70:120-127.
44. Lu H.H., Liu C.J., Liu T.Y., Kao S.Y., Lin S.C., Chang K.W. Areca-treated fibroblasts enhance tumorigenesis of oral epithelial cells. J. Dent. Res. 2008, 87:1069-1074.
45. Rosenthal E.L., McCrory A., Talbert M., Carroll W., Magnuson J.S., Peters G.E. Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch. Otolaryngol. Head. Neck. Surg. 2004, 130:943-947.
46. Al-Hazmi N., Thomas G.J., Speight P.M., Whawell S.A. The 120kDa cell-binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing cells by increasing matrix metalloproteinase-2 and -9 secretion. Eur. J. Oral Sci. 2007, 115:454-458.
47. Aznavoorian S., Moore B.A., Alexander-Lister L.D., Hallit S.L., Windsor L.J., Engler J.A. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Res. 2001, 61:6264-6275.
48. Sun L., Diamond M.E., Ottaviano A.J., Joseph M.J., Ananthanarayan V., Munshi H.G. Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol. Cancer. Res. 2008, 6:10-20.
49. Munshi H.G., Wu Y.I., Mukhopadhyay S., Ottaviano A.J., Sassano A., Koblinski J.E., Platanias L.C., Stack M.S. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J. Biol. Chem. 2004, 279:39042-39050.
50. Ikeda M., Maekawa R., Tanaka H., Matsumoto M., Takeda Y., Tamura Y., Nemori R., Yoshioka T. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin. Cancer Res. 2000, 6:3290-3296.
51. Munshi H.G., Wu Y.I., Ariztia E.V., Stack M.S. Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J. Biol. Chem. 2002, 277:41480-41488.
52. Munshi H.G., Ghosh S., Mukhopadhyay S., Wu Y.I., Sen R., Green K.J., Stack M.S. Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J. Biol. Chem. 2002, 277:38159-38167.
53. Ara T., Deyama Y., Yoshimura Y., Higashino F., Shindoh M., Matsumoto A., Fukuda H. Membrane type 1-matrix metalloproteinase expression is regulated by E-cadherin through the suppression of mitogen-activated protein kinase cascade. Cancer Lett. 2000, 157:115-121.
54. Sang Q.X., Jin Y., Newcomer R.G., Monroe S.C., Fang X., Hurst D.R., Lee S., Cao Q., Schwartz M.A. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr. Top. Med. Chem. 2006, 6:289-316.
55. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19:6642-6650.
56. Ahonen M., Poukkula M., Baker A.H., Kashiwagi M., Nagase H., Eriksson J.E., Kahari V.M. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003, 22:2121-2134.
57. Bian J., Wang Y., Smith M.R., Kim H., Jacobs C., Jackman J., Kung H.F., Colburn N.H., Sun Y. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 1996, 17:1805-1811.
58. Devy L., Dransfield D.T. New strategies for the next generation of matrix-metalloproteinase inhibitors: Selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int. 2011, 2011:191670.
59. Dorman G., Cseh S., Hajdu I., Barna L., Konya D., Kupai K., Kovacs L., Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010, 70:949-964.
60. Heikkila P., Suojanen J., Pirila E., Vaananen A., Koivunen E., Sorsa T., Salo T. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int. J. Cancer 2006, 118:2202-2209.
61. Suojanen J., Sorsa T., Salo T. Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro. Oral Dis. 2009, 15:170-175.
62. Sakr M.A., Takino T., Domoto T., Nakano H., Wong R.W., Sasaki M., Nakanuma Y., Sato H. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer. Sci. 2010, 101:2368-2374.
63. Katori H., Baba Y., Imagawa Y., et al. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett. 2002, 178:151-159.
64. Thomas G.J., Hart I.R., Speight P.M., Marshall J.F. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br. J. Cancer 2002, 87:859-867.
65. Ramos D.M., But M., Regezi J., Schmidt B.L., Atakilit A., Dang D., Ellis D., Jordan R., Li X. Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 2002, 21:297-307.
66. Maekawa K., Sato H., Furukawa M., Yoshizaki T. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model. Clin. Exp. Metastasis 2002, 19:513-518.
67. Makinen L.K., Hayry V., Atula T., et al. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J. Oral Pathol. Med. 2011.
68. Chiang W.C., Wong Y.K., Lin S.C., Chang K.W., Liu C.J. Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression. Oral Dis. 2006, 12:27-33.
69. Hwang Y.S., Park K.K., Chung W.Y. Invadopodia formation in oral squamous cell carcinoma: the role of epidermal growth factor receptor signalling. Arch. Oral Biol. 2011.
70. Oridate N., Lotan D., Xu X.C., Hong W.K., Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 1996, 2:855-863.
71. Uchida D., Kawamata H., Nakashiro K., Omotehara F., Hino S., Hoque M.O., Begum N.M., Yoshida H., Sato M., Fujimori T. Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines. Br. J. Cancer 2001, 85:122-128.
72. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
73. Kurihara Y., Hatori M., Ando Y., Ito D., Toyoshima T., Tanaka M., Shintani S. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin. Exp. Metastasis 2009, 26:425-432.
74. Kinugasa Y., Hatori M., Ito H., Kurihara Y., Ito D., Nagumo M. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin. Exp. Metastasis 2004, 21:737-745.
75. Li W.Z., Huo Q.J., Wang X.Y., Xu F. Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. Prostaglandins Other Lipid Mediat. 2010, 93:113-119.
76. Chen P.N., Hsieh Y.S., Chiang C.L., Chiou H.L., Yang S.F., Chu S.C. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J. Dent. Res. 2006, 85:220-225.
77. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA 2001, 98:1024-1029.
78. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H., Pihlajaniemi T., Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J. Biol. Chem. 2003, 278:22404-22411.
79. Wilson R.F., Morse M.A., Pei P., Renner R.J., Schuller D.E., Robertson F.M., Mallery S.R. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res. 2003, 23:1289-1295.
80. Kylmaniemi M., Oikarinen A., Oikarinen K., Salo T. Effects of dexamethasone and cell proliferation on the expression of matrix metalloproteinases in human mucosal normal and malignant cells. J. Dent. Res. 1996, 75:919-926.
81. Ikebe T., Takeuchi H., Jimi E., Beppu M., Shinohara M., Shirasuna K. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int. J. Cancer 1998, 77:578-585.
82. Beppu M., Ikebe T., Shirasuna K. The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on NF-kappaB-mediated protease production by oral cancer. Biochim. Biophys. Acta. 2002, 1586:11-22.
83. Yan M., Xu Q., Zhang P., Zhou X.J., Zhang Z.Y., Chen W.T. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer 2010, 10:437.
84. Sinpitaksakul S.N., Pimkhaokham A., Sanchavanakit N., Pavasant P. TGF-beta1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway. Biochem. Biophys. Res. Commun. 2008, 371:713-718.
85. Takayama S., Hatori M., Kurihara Y., Kinugasa Y., Shirota T., Shintani S. Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases. Oncol. Rep. 2009, 21:205-210.
86. Gonelli A., Mischiati C., Guerrini R., Voltan R., Salvadori S., Zauli G. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev. Med. Chem. 2009, 9:498-509.
87. Tsai C.H., Hsieh Y.S., Yang S.F., Chou M.Y., Chang Y.C. Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: Preliminary observations. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 95:710-716.
88. Hamakawa H., Nakashiro K., Sumida T., Shintani S., Myers J.N., Takes R.P., Rinaldo A., Ferlito A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008, 30:800-809.
89. Lee E.J., Whang J.H., Jeon N.K., Kim J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann. N. Y. Acad. Sci. 2007, 1095:113-128.
90. Wen J., Nikitakis N.G., Chaisuparat R., et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am. J. Pathol. 2011, 178:2866-2878.
91. Lee S., Thiele C. Factors associated with free flap complications after head and neck reconstruction and the molecular basis of fibrotic tissue rearrangement in preirradiated soft tissue. J. Oral Maxillofac. Surg. 2010, 68:2169-2178.
92. Mueller C.K., Schultze-Mosgau S. Radiation-induced microenvironments-the molecular basis for free flap complications in the pre-irradiated field?. Radiother. Oncol. 2009, 93:581-585.
93. Mueller C.K., Thorwarth M., Schultze-Mosgau S. Late changes in cutaneous gene expression patterns after adjuvant treatment of oral squamous cell carcinoma (OSCC) by radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109:694-699.